Are there differences between serotonergic, noradrenergic and dual acting antidepressants in the treatment of depressed women?

Simple item page
dc.contributor.buuauthorEker, Salih Saygın
dc.contributor.buuauthorKırlı, Selçuk
dc.contributor.buuauthorAkkaya, Cengiz
dc.contributor.buuauthorCangür, Şengül
dc.contributor.buuauthorSarandöl, Aslı
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Psikiyatri Anabilim Dalı.tr_TR
dc.contributor.researcheridQ-9477-2019tr_TR
dc.contributor.scopusid14019347700tr_TR
dc.contributor.scopusid14019745700tr_TR
dc.contributor.scopusid14061855100tr_TR
dc.contributor.scopusid8604063700tr_TR
dc.contributor.scopusid14020405100tr_TR
dc.date.accessioned2022-01-20T12:36:45Z
dc.date.available2022-01-20T12:36:45Z
dc.date.issued2009
dc.description.abstractBackground. This study aims to investigate if there is a differential outcome of serotonergic and noradrenergic antidepressant treatment and if menopausal status has an impact on antidepressant response in depressed women. Methods. Data of the 111 depressed women who were included and completed the previous four open-label studies where patients were evaluated six times during a 10-week period, were pooled in the current study. Each of the reboxetine, sertraline and venlafaxine groups consisted of 37 depressed women. Patients were also divided into two subgroups of age, determining the 44 years as the cut-off point representing the menopausal status. Results. No significant difference was observed in the percent change of Hamilton Depression Rating Scale-17 (HDRS) and remission rates among treatment groups. Percent changes in Clinical Global Impression-Severity of Illness scale (CGI-S) and response rates were in favour of venlafaxine group at week 10. Individual HDRS items 2, 3, 4, 5 and 6 demonstrated significant improvement in the sertraline group, whereas HDRS item 7 demonstrated significant improvement in the venlafaxine group. An early reduction in anxiety subscale was observed in the venlafaxine group. Menopausal status had no impact on the outcome measures. Conclusions. These results suggest that noradrenergic and serotonergic activity do not differ from each other in treating depressed women. However, serotonergic activity appears to be more prominent in some particular symptoms such as feelings of guilt, suicidal ideation and sleep. Also, menopause does not appear to affect antidepressants' benefit in depressed women.en_US
dc.identifier.citationEker, S. S. vd. (2009). "Are there differences between serotonergic, noradrenergic and dual acting antidepressants in the treatment of depressed women?". World Journal of Biological Psychiatry, 10(4), Part 2, 400-408.en_US
dc.identifier.endpage408tr_TR
dc.identifier.issn1562-2975
dc.identifier.issue4, Part 2tr_TR
dc.identifier.pubmed19670086tr_TR
dc.identifier.scopus2-s2.0-77449098829tr_TR
dc.identifier.startpage400tr_TR
dc.identifier.urihttps://doi.org/10.1080/15622970903131886
dc.identifier.urihttps://www.tandfonline.com/doi/full/10.1080/15622970903131886
dc.identifier.urihttp://hdl.handle.net/11452/24198
dc.identifier.volume10tr_TR
dc.identifier.wos000273003200007tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherTaylor & Francisen_US
dc.relation.journalWorld Journal of Biological Psychiatryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAntidepressantsen_US
dc.subjectDepressionen_US
dc.subjectGenderen_US
dc.subjectNorepinephrine reuptake inhibitoren_US
dc.subjectGender-differencesen_US
dc.subjectSex-differencesen_US
dc.subjectPostmenopausal womenen_US
dc.subjectSelective serotoninen_US
dc.subjectDouble-blinden_US
dc.subject5-hydroxytryptamine(2a) receptorsen_US
dc.subjectEstrogen replacementen_US
dc.subject12-month prevalenceen_US
dc.subjectTreatment responseen_US
dc.subjectPsychiatryen_US
dc.subject.emtreeAlpha adrenergic receptor stimulating agenten_US
dc.subject.emtreeAntidepressant agenten_US
dc.subject.emtreeReboxetineen_US
dc.subject.emtreeSerotonin agonisten_US
dc.subject.emtreeSertralineen_US
dc.subject.emtreeVenlafaxineen_US
dc.subject.emtreeAdrenergic receptor affecting agenten_US
dc.subject.emtreeAntidepressant agenten_US
dc.subject.emtreeCyclohexanol derivativeen_US
dc.subject.emtreeMorpholine derivativeen_US
dc.subject.emtreeReboxetineen_US
dc.subject.emtreeSerotonin uptake inhibitoren_US
dc.subject.emtreeSertralineen_US
dc.subject.emtreeVenlafaxineen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeClinical Global Impression scaleen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDepressionen_US
dc.subject.emtreeDrug dose increaseen_US
dc.subject.emtreeDrug efficacyen_US
dc.subject.emtreeDrug mechanismen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHamilton scaleen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMenopauseen_US
dc.subject.emtreeRemissionen_US
dc.subject.emtreeAgeen_US
dc.subject.emtreeClimacteriumen_US
dc.subject.emtreeClinical trialen_US
dc.subject.emtreeComparative studyen_US
dc.subject.emtreeDrug combinationen_US
dc.subject.emtreeDrug effecten_US
dc.subject.emtreeMajor depressionen_US
dc.subject.emtreeMiddle ageden_US
dc.subject.emtreePersonality testen_US
dc.subject.emtreePsychological aspecten_US
dc.subject.emtreeRetrospective studyen_US
dc.subject.meshAdrenergic uptake inhibitorsen_US
dc.subject.meshAdulten_US
dc.subject.meshAge factorsen_US
dc.subject.meshAntidepressive agentsen_US
dc.subject.meshClimactericen_US
dc.subject.meshClinical trials as topicen_US
dc.subject.meshCyclohexanolsen_US
dc.subject.meshDepressive disorder, majoren_US
dc.subject.meshDrug therapy, combinationen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshMorpholinesen_US
dc.subject.meshPersonality inventoryen_US
dc.subject.meshRetrospective studiesen_US
dc.subject.meshSerotonin uptake inhibitorsen_US
dc.subject.meshSertralineen_US
dc.subject.meshYoung adulten_US
dc.subject.scopusDesvenlafaxine; Involutional Depression; Antidepressantsen_US
dc.subject.wosPsychiatryen_US
dc.titleAre there differences between serotonergic, noradrenergic and dual acting antidepressants in the treatment of depressed women?en_US
dc.typeArticle
dc.wos.quartileQ1en_US

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus